Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GLS | O94925 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14977352 | 0.85 | POLB (0.52) | POLBALDH1A1GLSATML3MBTL1 | |
| SCHEMBL11426727 | 0.82 | POLB (0.57) | POLBALDH1A1GLSATML3MBTL1 | |
| SCHEMBL10952699 | 0.79 | POLB (0.53) | POLBALDH1A1GLSATML3MBTL1 | |
| SCHEMBL7161882 | 0.76 | — | — | |
| SCHEMBL28432194 | 0.75 | POLB (0.41) | POLBALDH1A1GLSATMGAA | |
| SCHEMBL1968819 | 0.74 | ALDH1A1 (0.88) | POLBALDH1A1GLSATML3MBTL1 | |
| Chloroform SCHEMBL28257214 | 0.73 | ALDH1A1 (0.61) | POLBALDH1A1GLSATML3MBTL1 | |
| Hydrochloric Acid SCHEMBL20475888 | 0.72 | ALDH1A1 (0.85) | POLBALDH1A1GLSATML3MBTL1 | |
| SCHEMBL11412602 | 0.71 | ALDH1A1 (0.96) | POLBALDH1A1GLSATML3MBTL1 | |
| SCHEMBL94109 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428061-B2 | Autotaxin inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3253748-B1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124938-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016124938-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
| EP-0049071-A1 | N-arylbenzamide derivatives | ELI LILLY AND COMPANY (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | POLB 1170/4885ALDH1A1 4116/4885GLS 788/4885 |
| US-10428061-B2 | Autotaxin inhibitors | ENPP2, ATXN10, RNASE1 | POLB 1016/4885ALDH1A1 4227/4885GLS 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.